BPDCN

Blastic plasmacytoid dendritic neoplasm is commonly misdiagnosed as various forms of leukemia.

Click here to answer this week's poll.

ICYMI, this week we had stories about blastic plasmacytoid dendritic cell neoplasm, epidermolysis bullosa, an interview with Seth Matarasso, MD, and more.

Blastic plasmacytoid dendritis cell neoplasm is a rare and aggressive form of cancer that usually makes its appearance in the form of red to violet papules and plaques.

An expert weighs in on the latest updates in clinical research about this rare blood cancer that often manifests with cutaneous lesions.

A world leader in BPDCN explains how using social media can enhance dermatologists’ knowledge about this rare form of aggressive blood cancer.

A 13-year-old boy presenting an asymptotic dark violaceous infiltrated nodular lesion located on the left cheek was diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematologic malignancy that often presents with skin manifestations.

Click here to answer our weekly poll.

Rare aggressive cutaneous lymphoma puts patients at risk of thyroid and non-lymphocytic leukemia second primary malignancies, researchers say.

Researchers are looking at treating blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematolymphoid malignancy, with investigational agents equipped with different mechanisms of action, including XmAb14045 and IMGN632.

A recently published article details the clinical and biological features, and patient outcomes of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematopoietic malignancy.

B-cell lymphoma-2 inhibitor venetoclax has shown in clinical studies to improve symptoms with minimal toxicity in patients with cutaneous blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer that can be rapidly fatal without treatment.

Several CD123-targeted therapies have been in development following the FDA’s 2018 approval of tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), but important questions remain when it comes to targeting CD123 in myeloid malignancies.

A recent paper details the different ways scientists are investigating tagraxofusp to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematologic malignancy that often presents with skin manifestations.

Findings from a recent study support current recommendations to treat patients with BPDCN with tagraxofusp or hyper-CVAD as first-line treatments, then with allogeneic stem cell transplant if patients are eligible.

One expert who is part of a small worldwide group of dedicated scientists and clinicians working to build BPDCN awareness among specialists offers insights from his research for dermatologists.

Those who study blastic plasmacytoid dendritic cell neoplasm (BPDCN) struggle to make dermatologists and others aware that the rare hematologic malignancy that often first presents with skin manifestations exists.

Tagraxofusp, the first and only FDA-approved drug for blastic plasmacytoid dendritic cell neoplasm (BPDCN), outperforms traditional chemotherapy treatment for the rare myeloid malignancy.

The 10-year-old male presented after experiencing five months of bilateral knee joint pain. A bone marrow smear and biopsy revealed the boy had blastic plasmacytoid dendritic cell neoplasm. Doctors treated him and the patient achieved complete remission. The patient presented with a scalp rash one month after his first complete remission.

Studies are revealing clinical, molecular, diagnostic and therapeutic findings that are leading to a better understanding of blastic plasmacytoid dendritic cell neoplasm, and there are promising targeted treatments in the pipeline as well as a growing social media interest.

Dermatologists might be the first providers to encounter patients with blastic plasmacytoid dendritic cell neoplasm because more than 70% of these patients have cutaneous lesions. With one approved treatment and several in clinical trials, there are promising and much needed therapeutic options coming.

Blastic plasmacytoid dendritic neoplasm (BPDCN) is a rare but aggressive hematologic malignancy that often manifests with asymptomatic skin lesions that often appear as bruise-like lesions, plaques or nodules. With one approved drug available, researchers are studying additional investigational agents.

While little is known about BPDCN  and how to treat it, authors of a recent study suggest a low threshold for performing a skin biopsy to evaluate skin lesions in patients with hematological cancers, especially when those lesions that are quickly progressing, large or involve atypical sites.

Researchers make headway in determining life-prolonging treatment for blastic plasmacytoid dendritic cell neoplasm, a rare cancer that is often associated with skin manifestations.

Blastic plasmacytoid dendritic cell neoplasm isn’t a skin cancer. Yet, dermatologists might be the first providers to encounter these patients.